Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients
AbstractThe objectives of this review were to discuss standard and investigational treatment strategies for adolescent and young adult with acute myeloid leukemia, excluding acute promyelocytic leukemia. Acute myeloid leukemia (AML) in adolescent and young adult patients (AYAs) may need a different type of therapy than those currently used in children and older patients. As soon as AML is diagnosed, AYA patient should be offered to participate in well-designed clinical trials. The standard treatment approach for AYAs with AML is remission induction chemotherapy with an anthracycline/cytarabine combination, followed by either consolidation chemotherapy or stem cell transplantation, depending on the ability of the patient to tolerate intensive treatment and cytogenetic features. Presently, continuing progress of novel drugs targeting specific pathways in acute leukemia may bring AML treatment into a new era. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Seval, G.C.; Ozcan, M. Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients. J. Clin. Med. 2015, 4, 441-459.
Seval GC, Ozcan M. Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients. Journal of Clinical Medicine. 2015; 4(3):441-459.Chicago/Turabian Style
Seval, Guldane C.; Ozcan, Muhit. 2015. "Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients." J. Clin. Med. 4, no. 3: 441-459.